208 related articles for article (PubMed ID: 37992684)
1. Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Popescu B; Stahlhut C; Tarver TC; Wishner S; Lee BJ; Peretz CAC; Luck C; Phojanakong P; Camara Serrano JA; Hongo H; Rivera JM; Xirenayi S; Chukinas JA; Steri V; Tasian SK; Stieglitz E; Smith CC
Cell Rep Med; 2023 Nov; 4(11):101290. PubMed ID: 37992684
[TBL] [Abstract][Full Text] [Related]
2. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
Pfeiffer A; Franciosa G; Locard-Paulet M; Piga I; Reckzeh K; Vemulapalli V; Blacklow SC; Theilgaard-Mönch K; Jensen LJ; Olsen JV
Cancer Res; 2022 Jun; 82(11):2141-2155. PubMed ID: 35311954
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
5. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
6. AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.
Milnerowicz S; Maszewska J; Skowera P; Stelmach M; Lejman M
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958832
[TBL] [Abstract][Full Text] [Related]
7. Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia.
Seipel K; Graber C; Flückiger L; Bacher U; Pabst T
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360855
[TBL] [Abstract][Full Text] [Related]
8. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
9. TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax.
Tyagi A; Jaggupilli A; Ly S; Yuan B; El-Dana F; Hegde VL; Anand V; Kumar B; Puppala M; Yin Z; Wong STC; Mollard A; Vankayalapati H; Foulks JM; Warner SL; Daver N; Borthakur G; Battula VL
Leukemia; 2024 Jan; 38(1):82-95. PubMed ID: 38007585
[TBL] [Abstract][Full Text] [Related]
10. LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia.
Yu Z; Du J; Hui H; Kan S; Huo T; Zhao K; Wu T; Guo Q; Lu N
Theranostics; 2021; 11(1):93-106. PubMed ID: 33391463
[No Abstract] [Full Text] [Related]
11. AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill
Post SM; Ma H; Malaney P; Zhang X; Aitken MJL; Mak PY; Ruvolo VR; Yasuhiro T; Kozaki R; Chan LE; Ostermann LB; Konopleva M; Carter BZ; DiNardo C; Andreeff MD; Khoury JD; Ruvolo PP
Haematologica; 2022 Jun; 107(6):1311-1322. PubMed ID: 34732043
[TBL] [Abstract][Full Text] [Related]
12. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3/ITD acute leukemia cells through BIM activation.
Zhu R; Li L; Nguyen B; Seo J; Wu M; Seale T; Levis M; Duffield A; Hu Y; Small D
Signal Transduct Target Ther; 2021 May; 6(1):186. PubMed ID: 34024909
[TBL] [Abstract][Full Text] [Related]
13. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.
Peris I; Romero-Murillo S; Martínez-Balsalobre E; Farrington CC; Arriazu E; Marcotegui N; Jiménez-Muñoz M; Alburquerque-Prieto C; Torres-López A; Fresquet V; Martínez-Climent JA; Mateos MC; Cayuela ML; Narla G; Odero MD; Vicente C
Blood; 2023 Mar; 141(9):1047-1059. PubMed ID: 36455198
[TBL] [Abstract][Full Text] [Related]
14. Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.
Kelvin JM; Jain J; Thapa A; Qui M; Birnbaum LA; Moore SG; Zecca H; Summers RJ; Switchenko JM; Costanza E; Uricoli B; Wang X; Jui NT; Fu H; Du Y; DeRyckere D; Graham DK; Dreaden EC
Pharm Res; 2023 Sep; 40(9):2133-2146. PubMed ID: 37704893
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.
Park IK; Mishra A; Chandler J; Whitman SP; Marcucci G; Caligiuri MA
Blood; 2013 Mar; 121(11):2064-73. PubMed ID: 23321254
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1.
Janssen M; Schmidt C; Bruch PM; Blank MF; Rohde C; Waclawiczek A; Heid D; Renders S; Göllner S; Vierbaum L; Besenbeck B; Herbst SA; Knoll M; Kolb C; Przybylla A; Weidenauer K; Ludwig AK; Fabre M; Gu M; Schlenk RF; Stölzel F; Bornhäuser M; Röllig C; Platzbecker U; Baldus C; Serve H; Sauer T; Raffel S; Pabst C; Vassiliou G; Vick B; Jeremias I; Trumpp A; Krijgsveld J; Müller-Tidow C; Dietrich S
Blood; 2022 Dec; 140(24):2594-2610. PubMed ID: 35857899
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Bcl2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3.
Mehta SV; Shukla SN; Vora HH
Neoplasma; 2013; 60(6):666-75. PubMed ID: 23906301
[TBL] [Abstract][Full Text] [Related]
18. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia.
Brinton LT; Zhang P; Williams K; Canfield D; Orwick S; Sher S; Wasmuth R; Beaver L; Cempre C; Skinner J; Cannon M; Govande M; Harrington B; Lehman A; Byrd JC; Lapalombella R; Blachly JS
J Hematol Oncol; 2020 Oct; 13(1):139. PubMed ID: 33076970
[TBL] [Abstract][Full Text] [Related]
20. Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy.
Zhang W; Yu G; Zhang H; Basyal M; Ly C; Yuan B; Ruvolo V; Piya S; Bhattacharya S; Zhang Q; Borthakur G; Battula V; Konopleva M; Rice WG; Andreeff M
Haematologica; 2023 Jun; 108(6):1500-1514. PubMed ID: 36226489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
